What top creators are saying about Hims & Hers Health, Inc.(HIMS)

Price movement tracked at $28.01

The speaker views the 10% sell-off as nonsensical, comparing their products to inelastic staples with subscription-based demand that should resist economic downturns.

Aggressively expanding into the longevity market with a 90% recurring revenue model and high margins; viewed as a long-term hold that is currently undervalued despite heavy short interest.

Identified as a key player in the weight loss and telehealth space despite earnings volatility.

Showing resilience and technical strength moving toward the $30 price level.

Identified as an undervalued fintech/disruptor sector company ignored by the traditional financial establishment.

Strategic acquisition of Eucalyptus and strong subscriber growth drive a bullish outlook; analyst considers the stock 'dirt cheap' with a 'Rule of 40' score of 49.

Described as 'dirt cheap' with strong ARR growth from the Eucalyptus acquisition; preferred long-term buy while market ignores fundamentals.

Significant $1.2 million insider buy, high gross margins (74%), and deep value valuation (0.1 EV/GP/RG) compared to AI momentum stocks.

Insider buys reported.

Primary beneficiary of a medical breakthrough in hair loss treatment.

Successful trade based on peptide expert thesis; speaker is a power user.

Bullish on personalized medicine; chart shows an inverse head and shoulders breakout pattern.

Beneficiary of the peptides (GLP-1) market; the recent dip is viewed as a base-building exercise before an explosive move.

The market overreacted to a 0% interest convertible debt offering; the company is using funds for high-growth AI integration and the Eucalyptus acquisition, creating a 'buy the dip' opportunity.

Taking advantage of high stock prices to raise capital, leading to dilution concerns.

Recent loser in portfolio following poor earnings report; highlights volatility in mid-cap growth.

Currently being researched as a potential candidate for the next wave of the peptide/weight loss trend.

Financials are slowing and chart looks poor; avoid until it hits the $17-$20 range.

Benefit from the 'peptide explosion' and high social demand for weight loss treatments.

The stock dropped 20% despite increasing guidance, creating a potential divergence in value compared to the overheated AI sector.

Noted for a brutal 14% drop in price.

Trader Kevin Xu has exited his position, indicating a loss of confidence or a shift in strategy away from the stock.

Investor exited the position for a 5% loss to reallocate capital elsewhere.

Kevin Xu has initiated a trade to sell this position.

Interesting narrative play at the intersection of telehealth and peptides, though currently lacks high conviction.

The analyst views the 13% price drop as a massive disconnect from fundamentals, citing strategic GLP-1 momentum, high-margin subscription fees, and conservative management guidance as reasons for a strong buy opportunity.

Reported a 'double miss' in earnings, leading to an 8% drop in after-hours trading.

The company is seen as a 'sandbagger' with conservative guidance; massive growth in international markets and AI-driven diagnostics are key catalysts despite stock volatility.

Author expects the stock to recover from a 10% intraday decline caused by low trading volume ahead of the earnings call.

Experienced a 'double miss' on earnings resulting in an 8% drop, though retail investor positioning remains long.

Trading at a significant discount with an EV/GP/RG of 0.11; the market has not priced in the Eucalyptus acquisition or the rollout of branded GLP-1 products.

Potential removal of FDA Commissioner Marty Makary is seen as a bullish catalyst that could ease regulatory pressure on the company's compounded GLP-1 medications.

Author views the recent 47% decline as a long-term buying opportunity despite volatility, noting a 5.09% daily gain to $29.71.

Positioned as a 'peptide trade' with a massive addressable market for weight loss and hair growth treatments.

High consumer demand for peptides and 34% short interest ahead of earnings; risk of Novo Nordisk lawsuit and margin compression from Wegovy distribution.

Vanguard established a massive 20.9 million share position; high short interest of 34% suggests potential for a short squeeze.

High-conviction trade based on weight loss/peptide demand and potential for a short squeeze due to 34% short interest.

High short interest of 35% creates short squeeze potential, while AI integration and a more favorable regulatory environment at the FDA serve as significant bullish catalysts.

High social media sentiment and 34% short interest suggest potential for a short squeeze ahead of Q1 earnings, with recent insider or large-scale buying at $26.72.

Mentioned as a relevant ticker in the current market discussion.

Expected to benefit from lighter enforcement on compounded GLP-1s and telehealth services under new FDA leadership.

Investor is all-in at $26.72, anticipating a short squeeze due to 34% short interest and earnings on May 11, despite a lawsuit from Novo Nordisk.

Trading at an extremely cheap valuation despite strong growth and new GLP-1 partnerships.

The restoration of mail-order access for Mifepristone supports the growth of telehealth platforms specializing in reproductive health.

Host took a position based on personal product usage and following moves by respected community analysts.

Host exited position warning of a potential cool-down after a successful trade leg.

Highlighted as a retail 'hallucination yield' play driven by AI suggestions.

Viewed as a less attractive alternative to LFMD which owns its own supply chain.

Positive price action described as a 'sick candle' indicating strong upward momentum.